Thoratec Should Sever Link Between International And U.S. Websites FDA
This article was originally published in The Gray Sheet
Executive Summary
Thoratec Laboratories Corp. disputes FDA's assertions in an Aug. 12 warning letter that the company misbranded its VAD device and inappropriately promoted its TLC-II portable VAD driver, which is currently under an approved investigational device exemption.
You may also be interested in...
Abiomed
Approval of a "bridge-to-transplant" indication for the BVS-5000 device has never been sought by the company, as was reported in "The Gray Sheet" (1Aug. 30, p. 11). The device is approved for temporary cardiac support for post-cardiotomy shock, cardiac transplant failure, myocarditis, and right-ventricular assist while the patient is on an implantable left ventricular assist device
Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking
Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.